Loading research and source information…
Type 2 diabetes · Drug research
The registry reports active not recruiting. This is trial metadata, not an assessment of treatment benefit.
Evidence 1Content updated Oct 28, 2026 · Sources last checked Oct 28, 2026
Inclusion Criteria: * ■ Have been diagnosed with type 2 diabetes mellitus (T2DM); * Metformin is used in screening : 1) After used stable-dose metformin (≥1500 mg/day) or maximum tolerated (\< 1500mg but≥1000mg daily) for 8 weeks before screening； 2)Metformin treatment dose \<1500mg/day at Screening and have not reached the maximum tolerated dose ；3) Metformin combined with daily fixed-dose sulfonylureas (minimum therapeutic dose on the drug label) had been stable for ≥8 weeks when entering the induction period. * Have a BMI ≥23 kilograms per meter squared (kg/m²) at screening; * Be of stable weight (± 5%) for at least 3 months before screening; * Have HbA1c between ≥7.5% and ≤11.0%； Exclusion Criteria: * ■ Previous diagnosis of type 1 diabetes, special type diabetes; * There are malignant tumors within 5 years before screening, or patients are in latent of clinical malignant tumors (except patients with skin basal cell carcinoma and squamous cell carcinoma, cervical carcinoma in situ, prostate carcinoma in situ or papillary thyroid carcinoma who have no recurrence after surgery). * Have had chronic or acute pancreatitis any time prior to study entry; * Known allergic constitution (allergy to 3 or more kinds of food or drugs), or allergy to GLP-1 receptor agonists, or severe allergic diseases (asthma, urticaria, eczematous dermatitis, etc.) at screening; * Mentally incapacitated or speech-impaired; * Suspected or confirmed history of alcohol or drug abuse; * Pregnant or lactating woman; * The investigator considers that there are any other conditions that make it inappropriate to participate in this study.
This record covers only the linked trial population. This registry-based page does not review FDA approval or labeling.
FDA approval not reviewed here
Type 2 diabetes
See FDA labeling for the approved population and indication; this page covers the trial population only.
FDA labeling has not been reviewed for this page. This does not mean the treatment is unapproved.
Approval is specific to the indication and population. It does not establish availability, reimbursement or suitability for an individual.
This study is continuing but is no longer enrolling new participants.
Read trial record and posted resultsStudy ages: 18 Years to 75 Years. Other eligibility criteria apply; see the full criteria above.
Study countries and territories (including sites that may be closed): China.
Primary data collection: Nov 14, 2026 (estimated). This is not a results-release date.
No results-posting date in this record.
Evidence 1registry · Registry metadata is submitted by the sponsor or responsible party and does not independently validate efficacy.
No posted registry results are indicated in this source response. This does not establish that no results exist elsewhere.
Limitations: Outcomes, effect estimates, uncertainty and study quality have not been appraised. Consult original results and publications.
Evidence 1A Study of BGM0504 in Participants With Type 2 Diabetes
registry · NCT06716216 · Structured source fields
Source date: Oct 15, 2026 · Checked: Oct 28, 2026
Evidence location: protocolSection: identificationModule, statusModule, conditionsModule, armsInterventionsModule, designModule, outcomesModule, eligibilityModule, contactsLocationsModule, sponsorCollaboratorsModule; hasResults
Status: ACTIVE_NOT_RECRUITING. Phase: PHASE3. Conditions: Type 2 Diabetes Mellitus (T2DM).
Open original source